Log In
BCIQ
Print this Print this
 

Janumet, sitagliptin/metformin (MK-0431A) (ONO-5435A)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionCombination of Januvia sitagliptin phosphate plus metformin
Molecular Target Dipeptidyl peptidase-4 (DPP-4) (CD26) ; AMP-activated protein kinase (AMPK)
Mechanism of ActionAMP-activated protein kinase (AMPK) activator; Dipeptidyl peptidase-4 (DPP-4) inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation
PartnerOno Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$10.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/03/2009

Undisclosed

$10.0M

Undisclosed

Get a free BioCentury trial today